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of their relatives with schizophrenia were c292 (424), which corresponds to approxi-
mately 14% of the mean gross income of caregivers. Large expenditure items were 
groceries, clothes, rent and travel. CONCLUSIONS: The objective burden adds half-
time to an ordinary fulltime job (time spent on care) and additionally reduces gross 
incomes with approximately 14% (money spent on care) for informal caregivers to 
patients with schizophrenia spectrum disorders. 
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OBJECTIVES: To examine risk of discontinuation of antipsychotics following dis-
charge from acute care settings in Florida for Medicaid-enrolled persons with schizo-
phrenia. METHODS: Medicaid claims, enrollment data, and community services data 
from the state mental health authority from 2004–2008 were used. Demographics, 
diagnosis, service history during the year before admission to acute care (hospitals and 
crisis units), and post-discharge psychopharmacologic treatment were obtained. 
Persons who received antipsychotic monotherapy and had a discharge diagnosis of 
schizophrenia were included. Cox proportional hazards regression estimated risk of 
post-discharge discontinuation of antipsychotics (formulary restrictions were not con-
sidered). Second-generation antipsychotics (SGAs) were examined individually; oral 
ﬁ rst-generation antipsychotics (FGAs) and depot FGAs were each considered as a 
group. Demographics, pre-admission service history, length of stay, and pre-discharge 
length of time receiving medication were control variables. Data were right-censored 
at end of Medicaid enrollment, end of data availability, or death. RESULTS: Partici-
pants (N = 6365) were 42.7 ± 11.2 (mean ± SD) years old; 61% male; 34% white. 
Mean ± SD length of acute care stay was 11.0 ± 19.7 days. Median length of time 
receiving medication post-discharge was 45 days. With risperidone long-acting therapy 
(RLAT) as reference, depot and oral FGAs had highest risk of discontinuation (hazard 
ratio [HR] = 2.49, P < .0001 and HR = 1.68, P = .0005), respectively. Risk was also 
elevated for oral SGAs aripiprazole (HR = 1.65, P = .0012), ziprasidone (HR = 1.46, 
P = .0191), olanzapine (HR = 1.43, P = .0202), and quetiapine (HR = 1.35, P = .0434), 
except for oral risperidone and clozapine. Fewer months receiving pre-discharge 
medication (HR = 1.04, P < .0001), black race (HR = 1.39, P < .0001), history of 
involuntary commitment (HR = 1.28, P < .0001), and more pre-admission acute care 
services (HR = 1.13, P = .0053) were associated with higher risk of discontinuation. 
CONCLUSIONS: Persons with schizophrenia taking oral and depot FGAs were at 
highest risk for discontinuation of medication after discharge from acute care. Those 
taking oral SGAs (except risperidone and clozapine) also may have higher risk of 
discontinuation than patients taking RLAT.
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OBJECTIVES: Non-adherence to antipsychotic therapy can lead to increased risks of 
relapse and rehospitalization. Long-acting injectable antipsychotics have been shown 
to be effective and well-tolerated, with increasing evidence of a potential beneﬁ t on 
adherence. At the time of this study, only one long-acting injectable atypical antipsy-
chotic entity—risperidone—was approved for patients with a diagnosis of schizophre-
nia. The objective of this study was to determine the medication adherence rates of 
Medicaid patients treated with either 1) oral risperidone only, or 2) long-acting inject-
able risperidone +/− oral risperidone. METHODS: Texas Medicaid prescription claims 
data from January 2006 to December 2008 were analyzed for patients with schizo-
phrenia. Records were assessed for a period of 18 months (6-month pre-index period 
with no antipsychotics plus 12-month post-index period). a medication possession 
(MPR) ratio of ≥80% was considered adherent. RESULTS: A total of 1313 patients 
met inclusion criteria, and less than half, 48% (N = 626) had an MPR of at least 80%. 
Of the patients on long-acting injectables +/− oral risperidone, 60% (N = 96/160) were 
adherent with their regimen versus 46% (530/1153) for patients taking only oral 
risperidone. a logistic regression analysis adjusting for demographic covariates 
(gender, race, age) showed that patients on injectable +/− oral medications were about 
80 percent more likely to be adherent (OR = 1.82, 95% CI = 1.29–2.55; p = 0.0006) 
than patients on oral medication alone. There were no statistically signiﬁ cant differ-
ences in any of the demographic characteristics between the two groups. CONCLU-
SIONS: Overall, about half of the patients did not meet the deﬁ nition for medication 
adherence (MPR ≥ 80%) one-year after their index date. Long-acting injectable ris-
peridone had a higher rate of adherence compared to oral risperidone alone. With the 
release of newer atypical long-acting injections (paliperidone and olanzapine), future 
studies comparing adherence rates of these antipsychotic agents are needed.
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OBJECTIVES: Schizophrenia has been found to be associated with poor medication 
compliance, and a higher prevalence of diabetes. Once a hypoglycemic therapy is 
started, appropriate compliance to the therapy is crucial for good glycemic control. 
This study aimed to compare hypoglycemic therapy medication compliance, and 
health care costs after the initiation of the therapy, between type II diabetics with 
schizophrenia versus those without schizophrenia. METHODS: This study used the 
claims database of the National Health Insurance program. Enrollees who began oral 
hypoglycemic therapy in 2001–2002 (the index date), and had been diagnosed with 
schizophrenia and reﬁ lled at least one prescription of antipsychotic(s) in the year prior 
to the index date were included in the study (the case group). Enrollees without 
schizophrenia who began oral hypoglycemic therapy in 2001–2002 were selected from 
a randomly selected sample of the enrollees (the comparison group). Good medication 
compliance was deﬁ ned as an medication possession ratio (MPR) ≥ 0.8. Ordered 
logistic models were adopted to assess associations between factors with medication 
compliance. RESULTS: There were 1196 and 3188 subjects in the case group and 
comparison group, respectively. Forty-one percent of the case group and 30% of the 
comparison group were good compliant. The cost of hypoglycemic therapy was sig-
niﬁ cantly higher in the case group, while the total diabetes-related cost was not sig-
niﬁ cantly different between the two groups. The regression results indicated that 
comorbid schizophrenia was correlated with a higher likelihood of good compliance. 
In a subgroup analysis of diabetics with schizophrenia, good compliance to antipsy-
chotics in the previous year was signiﬁ cantly associated with a greater probability of 
being better compliant with hypoglycemic therapy. CONCLUSIONS: Diabetics with 
schizophrenia, compared with those without such a condition, were more compliant 
in their hypoglycemic therapy, and had higher cost of hypoglycemic therapy in the 
ﬁ rst year of the therapy.
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OBJECTIVES: According to evidence from scientiﬁ c literature the ease of administra-
tion, such as once-daily dosing, improves the adherence and persistance of patients 
with the pharmaceutical therapy. Adherence and persistance are key success factors 
in the treatment of schizophrenic patients, as drug discontinuation or non-adherence 
increase the risk of relapse, which eventually results in reduced quality adjusted life-
years and increased cost of care by more acute hospitalization episodes. Our objective 
was to analyze the impact of once-daily dosing vs. twice daily dosing on the discon-
tinuation rate of pharmaceutical therapy among patients with schizophrenia. 
METHODS: Our real world analysis is based on aggregated data from the Hungarian 
National Health Insurance Fund database. We selected adult patients (between 18–65 
years) on quetiapine therapy with F20 schizoprenia ICD-10 code between January and 
March 2008. We compared the one-year discontinuation rate among once-daily vs. 
twice daily quetiapine users. Discontinuation was deﬁ ned as no prescribed antipsy-
chotic medication in the N05A ATC group between May—July 2009. RESULTS: 
After 1 year 23.4% in the once-daily group compared to 27.2% in the twice-daily 
group discontinued the pharmaceutical therapy. Once-daily dosing reduced the rela-
tive risk of discontinuation by 13.9%. (χ2 test: p = 0,017). The absoluate risk reduction 
was 3.8% (NNT = 26.5). CONCLUSIONS: Our analysis indicates that once-daily 
dosing reduces the risk of drug discontinuation among schizophrenic patients. Short 
time-horizon, potential selection bias and confounding factors may limit the generaliz-
ability of our conclusions. Long-term observational study with multiple regression 
analysis based on anonimized individual patient records can conﬁ rm the validity of 
our ﬁ ndings.
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OBJECTIVES: Innovative antidepressants such as SSRIs and SNRIs have been widely 
adopted. However, the differences in patient antidepressant adherence and associated 
health care spending across patient factors and antidepressant choice needed further 
research. This study was trying to understand how patient factors and antidepressant 
choice inﬂ uenced medication adherence and associated health care expenditure. 
METHODS: A retrospective cross-sectional study was conducted using the 2000–
2007 Medical Expenditure Panel Survey (MEPS) database. a multiple OLS regression 
was used to examine MDD patient’s antidepressant adherence measured by propor-
tional days covered (PDC). a two-part model was implemented to study the impact 
of MDD patient factors and antidepressant choice on associated health care expendi-
ture. RESULTS: Linear regression models indicated that patient gender, ethnicity and 
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health insurance status were associated with differential levels of antidepressant adher-
ence and associated health expenditure. Hispanic ethnicity was associated with 
decreased antidepressant adherence compared to non-Hispanic white (β = 12.53, P < 
0.05) and other ethnicities (β = 28.27, P < 0.01). Patient who were covered by public 
insurance had better PDC compared to uninsured patients (β = 16.23, P < 0.05). 
Patient who were covered by private insurance spent more on MDD-speciﬁ c drug 
compared to uninsured patients (β = 0.36, P < 0.05). Higher antidepressant adherence 
was associated with higher MDD-speciﬁ c drug expenditure (β = 0.03, P < 0.01). Use 
of innovative antidepressants such as SSRIs and SNRIs was associated with an increase 
in MDD-speciﬁ c drug expenditure. CONCLUSIONS: Differences in antidepressant 
adherence and health care spending across patient factors could have important policy 
implications for drug formularies and health disparities. Solutions for gaps between 
optimal and suboptimal health care for patient mental health caused by systematic 
differences in sociological factors need to be well tailored. We need policy makers to 
be engaged in designing effective policy interventions to improve patient medication 
adherence, and to fund cost-effectiveness studies to improve patient outcomes and in 
turn, reduce associated health expenditure.
PMH50
TRENDS IN ANTIDEPRESSANT UTILIZATION, AND ASSOCIATED 
LABOR MARKET PARTICIPATION AND QUALITY OF LIFE OUTCOMES 
IN THE UNITED STATES: 2004–2007
Lin HC1, Erickson S2, Smith D1, Balkrishnan R2
1University of Michigan, Ann Arbor, MI, USA; 2University of Michigan, College of Pharmacy, 
Ann Arbor, MI, USA
OBJECTIVES: Innovative antidepressants have been widely adopted. However, the 
differences in patient factors and antidepressant use, and associated patient health and 
work outcomes were not jointly studied. This study was trying to understand how 
patient factors and antidepressant utilization were associated with patient employment 
durations and quality of life. METHODS: A retrospective cross-sectional study was 
conducted using the 2004–2007 Medical Expenditure Panel Survey (MEPS) database. 
Proportional hazard duration models were used to examine MDD patient’s employ-
ment duration. Linear regression models were implemented to study the impacts of 
MDD patient factors and antidepressant utilization on associated patient physical and 
mental health status. RESULTS: Differences in employment duration across several 
patient factors were found. Cox proportional hazard model showed that, compared 
to uninsured patients, MDD patients covered by private insurance had a lower level 
of hazard of job termination (hazard ratio = 0.15, P < 0.01). Patients who were in 
better physical health conditions had a lower level of hazard of job termination 
(hazard ratio = 0.96, P < 0.01). Results from OLS regressions showed that, compared 
to patient without antidepressant pharmacotherapy for MDD treatment, patients who 
took innovative antidepressants such as SSRIs/SNRIs and other newer ones had a huge 
increase in MCS (β = 11.35, P < 0.01). In addition, better antidepressant adherence 
was signiﬁ cantly associated with an increase of MCS (β = 0.10, P < 0.01). CONCLU-
SIONS: This study suggested that effective policy interventions were needed for 
improving medication adherence, and the design of prescription drug beneﬁ t within 
health insurance should be tailored considering its associations with patient factors 
and related improvement in health status according to the ﬁ ndings of this study. We 
need policy makers to be engaged in designing effective policy interventions to improve 
patient medication adherence, which may in turn improve patient health status and 
labor market participation.
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OBJECTIVES: To assess cost-of-illness and patient-relevant outcomes in patients with 
dementia in different settings in the German health system. METHODS: 600 patients 
with dementia were recruited at 1) a university hospital; 2) general practitioners; 3) 
ofﬁ ce-based neurologists; 4) a regional psychiatric hospital; and 5) in long-term care 
facilities. Socio-demographic, economic and clinical parameters were assessed using a 
standardized questionnaire. Disease severity was measured by means of the Minimen-
tal Status Examination (MMSE) and the Alzheimer’s Disease Assessment Scale. Neu-
ropsychiatric status was assessed with the Geriatric Depression Scale, the 
Neuropsychiatric Inventory and the Alzheimer’s Disease Cooperative-Study-Activities 
of Daily Living. Patient’s quality of life was reported by the patient and also by the 
caregiver (employing the EuroQol and the QoL-AD instruments). RESULTS: For an 
interim analysis, 278 patients (180 female, 98 male) were available. Mean age was 
78.2 yrs and mean disease duration was 4.5 yrs (SD 3.9). On average, care was needed 
for 3.0 yrs (SD 3.1). Cognitive impairment was severest in institutionalized patients 
(MMSE 12.2 pts SD 8.2) compared to the mean of all patients (MMSE 16.9 Pts). 
Mean EQ VAS values were 60.5 pts (SD 20.2). Disease-speciﬁ c QoL-AD health status 
mean was 30.2 (SD 5.6). Health status was rated highest in long-term care facilities 
(EQ VAS) and at ofﬁ ce-based neurologists (QoL-AD). In all severity stages patients 
rated their own health status (Qol-AD) better than their relatives. The costs of anti-
dementia drugs were c45,000 per 3 months. Memantine accounted for 61%. a total 
of 41% of the patients received Memantine whereas 45% of the patients received no 
anti-dementia medication. CONCLUSIONS: Health status is considerably impaired 
in patients with dementia and their caregivers. Interestingly, caregivers often appraise 
patients’ Quality of life worse than the patients themselves. Altogether, our results 
indicate a considerable under-supply with anti-dementia drugs.
PMH52
A SHORT 12-ITEM ZARIT BURDEN INVENTORY FOR THE ASSESSMENT 
OF DEMENTIA CAREGIVERS AS OBTAINED BY ITEM RESPONSE 
THEORY
Ballesteros J1, Santos B1, González-Fraile E2, Muñoz-Hermoso P2, Dominguez-Pachón A3, 
Martín-Carrasco M4
1University of the Basque Country, UPV/EHU, CIBERSAM, Leioa, Spain; 2Instituto de 
Investigaciones Psiquiátricas-IIP, Bilbao, Spain; 3Hospital Aita Menni, Arrasate-Mondragón, 
Spain; 4Clínica Psiquiátrica Padre Menni, Pamplona, Spain
OBJECTIVES: The Zarit Burden Inventory (ZBI) is a 22-item self-report scale fre-
quently used to asess patients’ caregiver burden on several dimensions. As a multidi-
mensional instrument the interpretation of its total score is sometimes unclear. Our 
aim was to obtain a short-ZBI unidimensional scale based on Item Response Theory 
(IRT) approaches. METHODS: The validation sample comprised 246 caregivers of 
patients diagnosed with dementia and recruited for an ongoing multi-center random-
ized clinical trial on the efﬁ cacy of psychoeducational interventions (EDUCA-2 trial). 
The pre-randomization 22-item ZBI was analyzed according to the Samejima’s graded 
response model to select the more informative items. The dimensionality of the scale 
was further tested with Conﬁ rmatory Factor Analysis (CFA). Finally, discriminant 
validity was assessed by Receiving Operator Characteristic (ROC) analysis and the 
Area Under the Curve (AUC) contrasting the short scale total score against the psy-
chological distress criterion evaluated with the General Health Questionnaire 28-item 
at 5/6 cut-off. RESULTS: A 12-item short-ZBI was selected. It covered 87% of the 
total 22-item ZBI information and showed appropriate item curve characteristics 
according to the Samejima’s model. The short-ZBI had an internal reliability of 0.89 
(Cronbach’s alpha), and was compatible with a unidimensional latent structure for 
the burden construct (CFI = 0.99; RMSEA = 0.05). According to the GHQ-28 cut-off 
131 caregivers (53% of the total sample) could be considered at high risk for develop-
ping psychological distress. The discriminant validity of the short-ZBI scale against 
that criterion was good (AUC = 0.84, 95% CI = 0.79 to 0.89) and not signiﬁ cantly 
different from the parental 22-item ZBI (p = 0.85). CONCLUSIONS: We have found 
good psychometric properties for the short-ZBI scale derived from IRT. Its unidimen-
sionality might be important to enhance its interpretation. Further psychometric 
studies, mainly on its sensitivity to change are now warranted.
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OBJECTIVES: The literature indicates that social support is protective of relapse for 
adolescents treated for substance use disorder (SUD). Unfortunately, no standard 
measure of social support exists. The objective of this research is to use factor analysis 
to elucidate the underlying factor structure of a 14-item social support scale for use 
in outcomes assessment in this treatment population. METHODS: Subjects are 517 
adolescents discharged from primary substance abuse treatment from 2004–2008. The 
data is from research conducted between 6 and 12 months post discharge via a 234-
item questionnaire that included the 14-item social support scale. The scale has ques-
tions that assess the degree to which the adolescent’s social contacts conform to norms 
of positive behavior and therefore foster non-use and recovery. The response rate was 
62 percent. RESULTS: The factorability of the scale was assessed by Keiser-Meyer-
Olkin statistic (it was 0.727, > the recommended 0.6) and by Bartlett’s test of spheric-
ity which was signiﬁ cant (x2 = 1066.89, p = 0.00001). The scale was decomposed by 
principal component factor analysis and three factors emerged. Initial Eigen values 
explained 65.6, 23.1 and 11.3 percent of the variance, respectively. Final factor solu-
tions were examined using varimax, oblimin and promax rotations with 3, 4, 5 & 6 
solutions, respectively. a three-factor solution via promax explaining 99 percent of 
the variance emerged as the best solution although results were similar using the other 
rotations. Factor 1 yielded ten items that are attributes of a peers’ potential to be 
positive a or negative inﬂ uence and thus supportive of recovery. The three items in 
Factor 2 related to emotional dimensions of social support. Factor 3 contained two 
items indicating a recovering adolescent’s ability to seek-out and establish positive 
social contacts. CONCLUSIONS: This scale is useful as a standard measure of social 
support which is an important aspect of treatment success.
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OBJECTIVES: In deciding about coverage of new medical technology, multiple clini-
cal outcomes are used to support reimbursement claims. Neither the real world value 
nor the relevance of these outcome measures for patients is systematically assessed. 
Hence, there is growing interest in the use of patient-reported outcome measures. 
Multi-criteria decision analysis, like the analytic hierarchy process (AHP), is a tech-
nique to elicit patient preferences. In the present study we used AHP to prioritize 
patient relevant endpoints related to the use of antidepressants in major depression. 
